Review our original research from global conferences


"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Conference Posters


AACR 2018

1016: Transcriptomic analysis of bulk tissues from a large PDX collection as a novel platform for discovering new TME targets/drugs

1051: Mutation detection in patient-derived xenografts by whole exome sequencing and transcriptome sequencing

1144: Building Kras (G12D)/Trp53 null/Pdx1-cre (KPC) mouse homograft tumor models for the efficacy evaluation of combinatory immunotherapies

1264: Commensal microbiota is involved in anti-PD-1 mAb-mediated antitumor activity in a preclinical tumor model

2167: Efficacy assessment of the BTK inhibitor ibrutinib in de novo and viral-induced B cell lymphoma

3809: T cell activation through the inhibition of tumor-expressed IDO1 activity in the tryptophan metabolism pathway

3861: 3D ex vivo PDX cell model screening to better predict in vivo outcomes

4059: Vaccination causes a clear subtype shift of tumor infiltrating Treg cells in mouse breast cancer homografts

4556: Phagocytosis response of macrophages to the CD47 expression of tumor cells in anti-CD47 therapy

5033: Patient-derived xenograft screening in a three-dimensional tumor growth assay incorporating stromal elements to recapitulate the human tumor microenvironment

5116: Development of murine tumor homograft panels and their genetic fingerprints for identification, to ensure quality controlled I/O studies using these models

5669: Establishment of a human CD3ε transgenic mouse model to assess anti-tumor efficacy of human T cell-redirecting bispecific antibodies

5677: Establishment and application of a panel of PBMC-humanized mouse tumor models in immuno-oncology and targeted cancer immunotherapy

5th Immunotherapy of Cancer Conference (iTOC5)

Establishment of Kras (G12D)/Trp53 null/Pdx1-cre (KPC) Mouse Homograft Tumor Models to Facilitate Preclinical Efficacy Evaluation of Combinatory Immunotherapies

2nd Annual Next Gen Immuno-Oncology Congress

Preclinical Efficacy Evaluation of Agonistic OX40 Human-Specific Therapeutic Antibodies in a Human OX40 Knock-In Mouse Model (HuGEMM™)

Tumor Models San Francisco

Transcriptomic Analysis of Patient-Derived Xenografts Reveals Heterogeneity in Human and Mouse Stroma/Immune Compartments

Characterization and Optimization of MiXeno™, PBMC-Humanized Mouse Tumor Models, for the Evaluation of the In Vivo Activity of Immunotherapeutics


Tumour Models London

Interrogation of Checkpoint Inhibitors in Bioluminescent Orthotopic Syngeneic Models of Hepatocellular Carcinoma

1st Northwest Gynecological Cancer Symposium

Establishment and Characterization of Human Ovarian Cancer Xenograft Models using Bioluminescence Imaging

2nd Annual World Preclinical Congress Europe

Preclinical Efficacy Evaluation of Agonistic OX40 Human-Specific Therapeutic Antibodies in a Human OX40 Knock-In Mouse Model (HuGEMM™)

Society for Immunotherapy of Cancer (SITC) Annual Meeting

P158: MiXeno™, hPBMC-derived humanized tumor model platform, is valuable in evaluating the antitumor efficacy of novel immuno-oncology drug candidates

4th AACR New Horizons in Cancer Research Conference

A27: Tumor-infiltrating MDSCs seem predictive of antitumor activity of a PD-1 antibody in a population-based syngeneic mouse tumor trial

A63: Establishment of Kras (G12D)/Trp53 null/Pdx1-cre (KPC) mouse allograft tumor models to facilitate preclinical efficacy evaluation of combinatory immunotherapies

A64: MuScreen™ allows profiling of antitumor efficacy and biomarker readouts of drug candidates using well-characterized syngeneic models

A65: Commensal microbiota is involved in anti-PD-1 mAb-mediated antitumor activity in a preclinical tumor model

B20: Survival analysis for PDX mouse clinical trials

B21: Determining combination effects in cell based assays

B59: Establishment of de novo and viral induced B lymphoma PDX models to evaluate efficacy of the BTK inhibitor ibrutinib

B73: Efficacy assessment of investigation human OX40 agonistic antibodies with human OX40 knock-in mouse models

B74: Development, characterization, and optimization of PBMC-humanized mouse tumor models, MiXeno™, as a valid platform to evaluate in vivo activities of immuno-oncology drug candidates

B75: Flow-based phenotyping of tumor-infiltrating immune cells in novel I/O models

B78: CD47 expression predicts efficacy of macrophage-mediated phagocytosis of tumor cells

B80: Pharmacological inhibition of syngeneic murine cancer cell proliferation by checkpoint inhibitors in combination with targeted agents


Short Talk: Transcriptomic Analysis of Patient-Derived Xenografts Reveals Heterogeneity in Human and Mouse Stroma/Immune Compartments

A003: Developing an AML mouse syngeneic model for combinatory chemotherapy and immunotherapy

A009: Evaluation of hormonal therapy in a panel of prostate patient-derived xenograft models and comparison to standard cell line models

A010: Interrogation of checkpoint inhibitors in bioluminescent orthotopic syngeneic models of hepatocellular carcinoma

A013: In-depth annotation of the world's largest patient-derived xenograft (PDX) library

A026: Analysis of cetuximab response in colon, gastric, and lung cancer PDX models

A203: Generation of human TIM-3 knock-in mice for preclinical efficacy assessment of therapeutic antibodies

A207: Utilizing human OX40 knock-in mice (HuGEMM™) to assess the antitumor efficacy of OX40 agonistic antibodies

A213: Three-dimensional tumor growth assay for patient-derived tissue and cell line models incorporating stromal elements for screening

B002: CD47 expression predicts efficacy of macrophage-mediated phagocytosis of tumor cells

B008: PD-1/PD-L1 blockade remarkably regulates abundance of gut commensal microbiota in a murine syngeneic tumor model

B014: MuScreen™ allows profiling of antitumor efficacy and biomarker readout of drug candidates using well-characterized syngeneic models

B078: MiXeno™: a fast and efficient humanized tumor model system for in vivo efficacy evaluation of novel immunotherapeutics

B209: Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments

AACR Tumor Immunology and Immunotherapy

A05: Involvement of Commensal Microbiota in aPD-1-Mediated Antitumor Activity in a Preclinical Tumor Model

A49: The Landscape of CD47 Expression in Tumor Cells Predicts Macrophage-Mediated Phagocytosis in Immuno-Oncology Therapy

B28: MiXeno™ is an Efficient Platform to Evaluate the In Vivo Activity of Human Antitumor Immunotherapeutics

5th Helmholtz Nature Medicine Diabetes Conference

Late Breaking Abstract: Lipids and Liver Fat Accumulation in Different Stages of Spontaneously Type 2 Diabetic Cynomolgus Monkeys

Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

A142: Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

Tumor Models Boston 2017

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

ADA 2017

1820: The Depletion of Peripheral NK Cells and NK T Lymphocytes in a Spontaneously Diabetic Non-Human Primate Model

1881: Rhythmic Differences of Blood Glucose Circadian between Normoglycemic and Diabetic Non-Human Primates

AACR 2017

396: Determining gene copy number variation via whole exome sequencing (WES) datasets from patient-derived xenografts

1647: Validation and characterization of MiXenoTM humanized mouse models for immuno-oncology

1658: Establishment of a CD137 humanized mouse model for efficacy assessment of agonistic anti-CD137 therapeutic antibodies

1665: MuScreenTM: An efficient and cost-effective in vivo screening platform using a panel of well-charcterized syngeneic tumor models

1829: Evaluation of checkpoint inhibitors on tumor infiltrating immune cells in the orthotopic and metastatic tumor microenvironment using bioluminescent syngeneic cell line models

2008: Intestinal microbiota may dynamically influence anti-PD-L1 immunotherapy

2696: Anti-PD-1 mAb treatment induces significant gut microbiota changes in the CT-26 colon cancer syngeneic model

2807: Developing a variety of primary mouse tumor allograft models for the evaluation of PARP inhibitors

2811: Comparative study of anti-PD-1 and CSF1R inhibition on tumor infiltrating lymphocytes and macrophage populations across a panel of syngeneic tumor models

2824: Validation of a panel of patient-derived xenograft models for prostate cancer and cell line models for preclinical drug evaluation

4203: Kinase inhibitor demonstrates efficacy in patient-derived xenograft model of fibrolamellar hepatocellular carcinoma featuring DNAJB1-PRKACA gene fusion

4534: Theory and methodology for the design and analysis of PDX mouse clinical trials

4707: Evaluation of efficacy and immune response to PD-1 checkpoint inhibition in human immune-reconstituted mice using patient-derived xenograft models

5597: Genomic profiling of syngeneic mouse cell lines and model in vitro screen against checkpoint inhibitors and targeted agents for preclinical applications


4th Annual Tumor Models Conference, Boston

A Panel of Well-Characterized Syngeneic Models for MuScreen™ In Vivo Screening

ADA 76th Scientific Sessions, New Orleans

79-LB: The Use of Dexcom G4 Continuous Glucose Monitoring in Diabetes NHP Research

308-LB: Characterization of FATZO Mice for Diabetes and Obesity Research

911-P: Advantages of Glucose Monitoring with an Implantable Telemetry Device in Freely Moving, Conscious Non-Human Primates

1822-P: Hepatic Lipidosis and Fibrosis in Obese, Dysmetabolic, and Diabetic Non-Human Primates Quantified by Noninvasive Sonography

AACR Annual Meeting, New Orleans

747: Autocrine c-Met/HGF HCC PDX: Evaluation of a Biologic Targeting c-Met

3219: Immunization is Critical to PD-1/PD- L1 Response in a Mouse Breast Cancer Allograft

3994: Immunology Syngeneic Models Demonstrate Additive Effects of Combination Strategies using Checkpoint Immunotherapy and Inducers of Immunogenic Cell Death (ICD)

4043: A Novel Mouse Skin Squamous Cell Carcinoma Allograft Model for In Vivo Pharmacological Analysis of Immunotherapy

5176: Orthotopic Syngeneic Tumor Models for Preclinical Evaluation of Cancer Immunotherapy Strategies

5177: RNAseq and FACS Profiling of Syngeneic Mouse Models Treated with Immune Checkpoint Inhibitors enable Biomarker Discovery and Model Selection for Cancer Immunotherapy

5179: Development of a Humanized Mouse Model for Direct Evaluation of Anti-Human PD-L1 Antibodies

5186: Using HuTrial™ to Aid in Predicting a Patient Population of Responders

6444: MiXeno™ Humanized Mouse Model as an Efficient Tool to Evaluate In Vivo Activity of Anti-Cancer Immunotherapeutics

ENDO 2016, Boston

SUN 720: Blood Glucose Fluctuations during Daily Activities and Stress Procedures in Cynomolgus Monkeys Monitored By Implanted Telemetry Device


AACR Annual Meeting, Philadelphia

765: Overcoming Acquired Resistance in NSCLC with Targeted Beam Irradiation in Combination with Targeted Agents

769: In Vivo Response and Molecular Characterization of a Caucasian NSCLC Squamous Cell Carcinoma PDX Sensitive to FGFR Inhibitors

1038: Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to PI3K/mTOR Dual Inhibitor BEZ235

1472: Building a Comprehensive and Fully Annotated Patient Tumor Derived Xenograft (PDX) Library Mirroring Cancer Patient Population

1802: Application of Small Animal Image-Guided Irradiation to Preclinical In Vivo Models such as Patient-Derived Xenografts to Inform on Combination Strategies

1926: Patient-Derived Xenograft Seem to Have Closer Global Expression Profile to that of Patient Tumors of the Corresponding Cancer Types, than the Equivalent Cell Lines Do

2281: Building Mouse Tumor Derived Allografts for Immuno-Oncology Research

3221: A Patient-Derived Xenograft (PDX) Platform for Development of Next Generation KIT Kinase Inhibitors in Imatinib-Resistant Gastrointestinal Tumors (GIST)

3224: Living Tumor Bank and Patient-Derived Xenograft Models: A Powerful Translational Engine for Novel Oncology Therapeutics

3226: Patient-Derived Xenograft (PDX) Models for Triple Negative Breast Cancer (TNBC): A Preclinical Platform for drug discovery

3235: Validation of Anti-Human PD-1 and PD-L1 Antibodies in MiXeno™ Mouse Models

3581: Rapid Conversion to Resistance of a Colon PDX with RET Fusion by Ponatinib Treatment Could Potentially Be Attributed to the Introduction of the Gate Keeper Mutation V804M

4209: Development of Patient-Derived Xenograft Models for Small Cell Lung Cancer as a Preclinical Platform for Drug Development

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston

247: Drug Resistant Murine Tumor Models Facilitate the Development of Next Generation Anticancer Therapeutics

382: Response to Checkpoint Inhibition by GEMM Breast Cancer Allograft

394: Induction of Resistances to Crizotinib in NSCLC Patient-Derived Xenograft Models Upon Treatment

396: Molecular Pathology of Patient Tumors, Patient-Derived Xenografts and Cancer Cell Lines

399: A HuGEMM h/mPD1 Mouse Model for Testing Anti-Human PD-1 Therapeutics

ADA 75th Scientific Sessions, Boston

Dynamic Changes of Betatrophin, Insulin, and Glucose during STZ Induction of Diabetes in Rhesus Monkeys

Long-term Continuous Glucose Monitoring in Conscious Stress-free Non-Human Primates with Implanted Telemetry Device

Effects of Anesthesia on Metabolic Responses to Mixed Meal Tolerance Test in Cynomolgus Monkeys

Left Ventricular Diastolic Dysfunction in Diabetic and Dysmetabolic Non-human Primates

ASH Annual Meeting, Orlando

2759: Activating Mutations in MYD88 and CD79B Are Predictive of Response to Ibrutinib in ABC-DLBCL Tumors

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York City

B115: Application of Image-Guided Irradiation to a Preclinical Bioluminescent Syngeneic Metastatic Breast Cancer Model in Combination with Immunotherapy to Inform on Combination Strategies

B117: Profiling of Syngeneic Models by Check Point Inhibitors, RNAseq, and FACS Analysis Enables Better Selection of Models for Immune Targeted Combination Therapy

18th ECCO, Vienna

228: Preclinical Mouse Trials (MCT) to Guide the Human Studies

201: Profiling of Syngeneic Models by Anti-PD-1, PD-L1 and CTLA-4 Immunotherapeutics and RNAseq Analysis Provides Predictive Biomarkers for Cancer Immunotherapy

New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients, Shanghai

A Novel RET TKI Inhibits Growth of Patient-Derived Xenografts with RET Fusion and Overcomes Ponatinib-Induced Resistance

Drug Resistant Murine Tumor Models Facilitate Development of Next Generation Anticancer Therapeutics

Establishment of a Humanized PD-1 Mouse Model for In Vivo Pharmacological Evaluation of Anti-Human PD-1 Antibodies

Establishment of a Mouse Breast Cancer Allograft Model for In Vivo Pharmacological Analysis of Immunotherapy

High Efficacy of a Novel and Specific c-MET TKI in a Cohort of PDXs from Selected NSCLC and HCC Patients

Immunological Characterization: Allograft of Primary Murine Breast Cancer (MuPrime™) versus Murine Breast Cancer Cell-Derived Syngeneic Tumors


AACR Annual Meeting, San Diego

1206: Parameters Influencing Design of Mouse Clinical Trial (HuTrial™)

2054: Patient Relevant Preclinical In Vivo Models Using Image-Guided Small Animal Irradiation for Drug Discovery

2562: Evaluate In Vivo Efficacy of Antitumor Immunotherapeutics Using MiXeno™ Mouse Models

3123: Modeling Anti-Leukemic Therapy by Patient-Derived AML Xenografts with Distinct Phenotypes/Genotypes

3124: Xenograft Models for Development of New Drugs Targeting Fibroblast Growth Factor Receptor (FGFR)

3136: X-MAN™ Isogenic DualXeno™ Models with KRAS Mutation Predicts the Effect of Anti-EGFR Agents

3440: Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to MEK Inhibitor Trametinib

4875: In Vivo and In Vitro Generation and Characterisation of EGFR-TKI Resistance in Patient-Derived Xenograft (PDX) and Cell Line Derived Xenograft (CDX) Models of NSCLC with Activating EGFR Mutations

AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics, Barcelona

Syngeneic Models for Developing Cancer Therapeutics Targeting Immune System

Treatment of Patient-Derived NSCLC Xenograft Preclinical Models Using Image-Guided Small Animal Irradiation

New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures, Shanghai

Development of a Gene Signature for Stratifying Cisplatin Treatment of NSCLC Patients

Induction of Resistance to Targeted Therapies in Patient-Derived Xenograft Models

Patient-Derived AML Xenografts for Drug Evaluation 

Request Time To Discuss a Poster

Your privacy is important to us.
We'll never share your information.